Table 2.
Baseline Patient Demographics and Characteristics
| Placebo (n = 25) | Dupilumab (n = 26) | SCIT (n = 26) | SCIT+dupilumab (n = 26) | |
|---|---|---|---|---|
| Age, mean (SD), years | 34.6 (11.1) | 40.3 (11.2) | 37.8 (11.3) | 33.0 (10.6) |
| ≥18 to ≤40 years, n (%) | 16 (64.0) | 12 (46.2) | 14 (53.8) | 18 (69.2) |
| ≥40 to ≤55 years, n (%) | 9 (36.0) | 14 (53.8) | 12 (46.2) | 8 (30.8) |
| Sex, male, n (%) | 15 (60.0) | 10 (38.5) | 12 (46.2) | 16 (61.5) |
| BMI, mean (SD) | 29.3 (10.25) | 28.0 (6.64) | 26.5 (5.26) | 26.6 (5.60) |
| TNSS AUC, mean (SD) | 5.34 (2.18) | 5.03 (2.19) | 4.66 (1.99) | 4.69 (1.72) |
| TNSS peak score, mean (SD) | 9.20 (1.56) | 8.50 (1.36) | 8.30 (1.19) | 8.70 (1.29) |
| TOSS AUC, mean (SD) | 2.75 (2.53) | 2.63 (2.88) | 2.80 (2.78) | 1.59 (1.92) |
| SPT AUC, mean (SD) | 13.74 (5.12) | 10.76 (4.73) | 12.87 (4.25) | 14.32 (5.95) |
| LPR wheal diameter, mean (SD) | 52.54 (23.80) | 48.79 (16.20) | 60.77 (34.10) | 46.40 (25.68) |
| PNIF AUC (0–1 h), mean (SD) | 80.89 (52.47) | 85.40 (46.76) | 77.86 (31.59) | 80.58 (36.46) |
| PNIF AUC (1–6 h), mean (SD) | 108.28 (47.09) | 114.07 (48.36) | 111.59 (36.03) | 113.38 (40.68) |
| Sneeze count AUC, mean (SD) | 0.68 (0.80) | 0.91 (1.11) | 0.45 (0.72) | 0.96 (1.17) |
| sIgE, mean (SD), kU/L | 27.212 (45.891) | 16.201 (35.427) | 18.776 (28.168) | 44.475 (126.639) |
| sIgG4, mean (SD), mg/L | 0.186 (0.170) | 0.213 (0.282) | 0.172 (0.216) | 0.221 (0.284) |
| sIgG, mean (SD), mg/L | 2.700 (1.503) | 2.804 (1.831) | 2.623 (1.421) | 3.858 (5.276) |
| log (sIgG4/sIgE), mean (SD) | −1.877 (0.694) | −1.596 (0.569) | −1.859 (0.550) | −1.871 (0.713) |
| log (sIgG/sIgE), mean (SD) | −0.659 (0.674) | −0.357 (0.642) | −0.603 (0.612) | −0.610 (0.620) |
| Total IgE, mean (SD), IU/mL | 159.756 (173.6115) | 159.769 (141.2617) | 222.508 (235.1932) | 364.258 (643.9095) |
| TARC, mean (SD), pg/mL | 280.8 (127.37) | 363.8 (219.45) | 350.8 (185.19) | 335.8 (205.86) |
| Patients with history of asthma, n (%) | 9 (36.0) | 7 (26.9) | 9 (34.6) | 10 (38.5) |
| Ongoing asthma, n/N1 (%) | 6/9 (66.7) | 4/7 (57.1) | 5/9 (55.6) | 6/10 (60.0) |
| Asthma patient with peak flow >80% predicted, n/N1 (%) | 9/9 (100) | 7/7 (100) | 8/9 (88.9) | 9/10 (90.0) |
Abbreviations: AUC, area under the curve; BMI, body mass index; IgE, immunoglobulin E; LPR, late-phase reaction; N1, number of patients with a history of asthma; PNIF, peak nasal inspiratory flow; SCIT, subcutaneous immunotherapy; SD, standard deviation; sIgE, timothy grass–specific immunoglobulin E; sIgG, timothy grass–specific immunoglobulin G; sIgG4, serum timothy grass–specific IgG4; SPT, skin prick test; TARC, thymus and activation-regulated chemokine; TNSS, total nasal symptom score; TOSS, total ocular symptom score.